Gross Profit Trends Compared: Takeda Pharmaceutical Company Limited vs Taro Pharmaceutical Industries Ltd.

Takeda vs. Taro: A Decade of Gross Profit Trends

__timestampTakeda Pharmaceutical Company LimitedTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 20141256834000000580006000
Thursday, January 1, 20151271973000000676585000
Friday, January 1, 20161173296000000778966000
Sunday, January 1, 20171274610000000671251000
Monday, January 1, 20181437534000000463508000
Tuesday, January 1, 20192201424000000445724000
Wednesday, January 1, 20202203504000000399725000
Friday, January 1, 20212462160000000296656000
Saturday, January 1, 20222783406000000293122000
Sunday, January 1, 20232832257000000268323000
Monday, January 1, 20242832257000000304979000
Loading chart...

Unleashing insights

Gross Profit Trends: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Takeda Pharmaceutical Company Limited and Taro Pharmaceutical Industries Ltd. over the past decade. Takeda, a Japanese multinational, has shown a remarkable growth trajectory, with its gross profit increasing by approximately 125% from 2014 to 2024. This growth is indicative of its strategic acquisitions and expanding global footprint.

Conversely, Taro, an Israeli-based company, experienced a decline of around 47% in gross profit over the same period. This trend highlights the challenges faced by smaller pharmaceutical firms in maintaining competitive advantage amidst industry giants. The data underscores the importance of strategic planning and market adaptation in the pharmaceutical sector. As we look to the future, these trends offer valuable insights into the financial health and strategic direction of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025